Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2022-07-19
- Last Posted Date
- 2025-05-07
- Target Recruit Count
- 200
- Registration Number
- NCT05464030
- Locations
- 🇺🇸
California Cancer Associates for Research & Excellence, Inc., Fresno, California, United States
🇺🇸Rhode Island Hospital, Providence, Rhode Island, United States
🇺🇸Mary Crowley Cancer Research, Dallas, Texas, United States
Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320)
- Conditions
- Metastatic or Locally Advanced Unresectable Solid Tumors
- Interventions
- First Posted Date
- 2022-05-31
- Last Posted Date
- 2025-05-21
- Target Recruit Count
- 123
- Registration Number
- NCT05396833
- Locations
- 🇺🇸
Providence Medical Foundation, Santa Rosa, California, United States
🇺🇸University of Miami School of Medicine, Miami, Florida, United States
🇺🇸Augusta University - formerly Georgia Regents University, Augusta, Georgia, United States
Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION)
- Conditions
- Head and Neck Cancer
- Interventions
- First Posted Date
- 2022-05-23
- Last Posted Date
- 2024-07-18
- Target Recruit Count
- 166
- Registration Number
- NCT05386550
- Locations
- 🇺🇸
University of Pittsburgh Medical Center Health System - UPMC Department of Dermatology, Pittsburgh, Pennsylvania, United States
🇨🇳Xiangya Hospital, Central South University, Changsha, China
🇨🇳Union Hospital, Tongji Medical College of Huazhong University of Science & Technology, Wuhan, China
Met Non Small Cell Cancer Registry (MOMENT)
- Conditions
- Cancer
- First Posted Date
- 2022-05-17
- Last Posted Date
- 2025-05-08
- Target Recruit Count
- 700
- Registration Number
- NCT05376891
- Locations
- 🇺🇸
The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
🇺🇸Holy Cross Health, Fort Lauderdale, Florida, United States
🇧🇪AZ Nikolaas, Sint-Niklaas, Belgium
A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)
- Conditions
- Locally Advanced or Metastatic Urothelial Carcinoma
- Interventions
- First Posted Date
- 2022-04-14
- Last Posted Date
- 2025-05-07
- Target Recruit Count
- 256
- Registration Number
- NCT05327530
- Locations
- 🇫🇷
Hôpital Henri Mondor - Service d'Oncologie Médicale, Creteil, France
🇫🇷Clinique Victor Hugo - Centre Jean Bernard - Service d'Oncologie Médical, Le Mans, France
🇫🇷Hopital Caremeau - Service Hématologie Clinique/Oncologie Médicale, Nîmes, France
First in Human Study of M1069 in Advanced Solid Tumors
- Conditions
- Metastatic or Locally Advanced Unresectable Solid Tumors
- Interventions
- First Posted Date
- 2022-01-20
- Last Posted Date
- 2024-11-25
- Target Recruit Count
- 15
- Registration Number
- NCT05198349
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇨🇦Princess Margaret Cancer Centre, Toronto, Canada
🇺🇸Sarah Cannon Research Institute (SCRI) (The SCRI Oncology Research Consortium), Nashville, Tennessee, United States
The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW)
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Drug: Enpatoran medium doseDrug: Enpatoran high doseDrug: Enpatoran low doseDrug: Placebo
- First Posted Date
- 2021-12-17
- Last Posted Date
- 2024-12-05
- Target Recruit Count
- 456
- Registration Number
- NCT05162586
- Locations
- 🇺🇸
The Lundquist Institute at Harbor-UCLA Medical Center, Torrance, California, United States
🇺🇸Bay Area Arthritis and Osteoporosis, Brandon, Florida, United States
🇺🇸Charisma Medical and Research Center, Miami Lakes, Florida, United States
Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS Tumors
- Conditions
- Central Nervous System Tumors
- Interventions
- First Posted Date
- 2021-10-18
- Last Posted Date
- 2025-04-15
- Target Recruit Count
- 17
- Registration Number
- NCT05081180
- Locations
- 🇨🇦
CHU Sainte-Justine, Montréal, Canada
🇨🇦The Hospital for Sick Children, Toronto, Canada
🇫🇷CHU Angers - Hôpital Hôtel Dieu - Service de Cancérologie Pédiatrique, Angers Cedex 9, France
Bintrafusp Alfa Program Rollover Study
- First Posted Date
- 2021-09-30
- Last Posted Date
- 2025-04-29
- Target Recruit Count
- 32
- Registration Number
- NCT05061823
- Locations
- 🇯🇵
Saitama Medical University International Medical Center, Hidaka-shi, Japan
🇺🇦Communal Enterprise Volyn Regional Medical Center of Oncology of Volyn Regional Council - Department of Oncochemotherapy, Lutsk, Ukraine
🇷🇺BHI of Omsk region "Clinical Oncology Dispensary" - PARENT, Omsk, Russian Federation
Next-Gen MS: Feed-forward PRO Data for MS Research
- Conditions
- Multiple Sclerosis (MS)
- First Posted Date
- 2021-05-28
- Last Posted Date
- 2024-06-06
- Target Recruit Count
- 1594
- Registration Number
- NCT04907305
- Locations
- 🇺🇸
Atlanta Neuroscience Institute, Atlanta, Georgia, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Alabama Neurology Associates, Birmingham, Alabama, United States